Global burden of COPD: risk factors, prevalence, and future trends

Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is a global health issue, with cigarette smoking being an important risk factor universally; other factors, such as exposure to indoor and outdoor air pollution, occupational hazards, and infections, are also important. As the global population ages, the burden of COPD will increase in years to come. Prevalence estimates of the disorder show considerable variability across populations, suggesting that risk factors can affect populations differently. Other advances in our understanding of COPD are increased recognition of the importance of comorbid disease, identification of different COPD phenotypes, and understanding how factors other than lung function affect outcome in our patients. The challenge we will all face in the next few years will be implementation of cost-effective prevention and management strategies to stem the tide of this disease and its cost.

[1]  D. Tashkin Smoked marijuana as a cause of lung injury. , 2005, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[2]  Dean T. Jamison,et al.  Measuring the Global Burden of Disease and Risk Factors, 1990–2001 , 2006 .

[3]  R. Luben,et al.  Area deprivation predicts lung function independently of education and social class , 2004, European Respiratory Journal.

[4]  A. Agustí Systemic effects of chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.

[5]  D. Sherrill,et al.  Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. , 1997, American journal of respiratory and critical care medicine.

[6]  T L Petty,et al.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. , 2000, Archives of internal medicine.

[7]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[8]  C. Fletcher The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London , 1976 .

[9]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[10]  T. Płusa [Epidemiology of chronic obstructive pulmonary disease]. , 2004, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[11]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[12]  M. Miravitlles,et al.  [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]. , 2004, Archivos de bronconeumologia.

[13]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[14]  T. Seemungal,et al.  COPD exacerbations: defining their cause and prevention , 2007, The Lancet.

[15]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[16]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[17]  J. Izquierdo,et al.  The burden of COPD in Spain: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[18]  Judith K Jones,et al.  Chronic obstructive pulmonary disease severity and cardiovascular outcomes , 2006, European Journal of Epidemiology.

[19]  S. Rennard,et al.  What have we learned from large drug treatment trials in COPD? , 2007, The Lancet.

[20]  Ramon Gisbert,et al.  Costs of chronic bronchitis and COPD: a 1-year follow-up study. , 2003, Chest.

[21]  Lung Chronic obstructive pulmonary disease , 1981 .

[22]  I. Adcock,et al.  Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase , 2004, The Lancet.

[23]  D. Lawlor,et al.  Association between self-reported childhood socioeconomic position and adult lung function: findings from the British Women’s Heart and Health Study , 2004, Thorax.

[24]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[25]  F. Raschke,et al.  Usefulness of GOLD classification of COPD severity , 2003, Thorax.

[26]  Ki Moon Bang,et al.  Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. , 2002, American journal of epidemiology.

[27]  N. Zhong,et al.  [The risk factors for chronic obstructive pulmonary disease in females in Chinese rural areas]. , 2006, Zhonghua nei ke za zhi.

[28]  N. Anthonisen The British hypothesis revisited , 2004, European Respiratory Journal.

[29]  G. Davey Smith,et al.  The natural history of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[30]  R. West,et al.  Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample , 2006, Thorax.

[31]  F. Blasi,et al.  Anxiety and depression in COPD patients: The roles of gender and disease severity. , 2006, Respiratory medicine.

[32]  B. Celli,et al.  Gender and COPD in patients attending a pulmonary clinic. , 2006, Chest.

[33]  Fernando Holguin,et al.  Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. , 2005, Chest.

[34]  M. Decramer,et al.  Systemic effects of COPD. , 2005, Respiratory medicine.

[35]  P. Calverley,et al.  Chronic obstructive pulmonary disease , 2003, The Lancet.

[36]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[37]  J. Vestbo,et al.  COPD: the dangerous underestimate of 15% , 2006, The Lancet.

[38]  D. Górecka,et al.  Smokers with airway obstruction are more likely to quit smoking , 2006, Thorax.

[39]  R. Vermeulen,et al.  Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers , 2006, Thorax.

[40]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[41]  D. Mannino,et al.  Lung function decline and outcomes in an elderly population , 2005, Thorax.

[42]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[43]  Joseph Menzin,et al.  Assessment of the Economic Burden of COPD in the U.S.: A Review and Synthesis of the Literature , 2006, COPD.

[44]  Ramon Gisbert,et al.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.

[45]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[46]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[47]  J. Hogg,et al.  Pathophysiology of airflow limitation in chronic obstructive pulmonary disease , 2004, The Lancet.

[48]  R. Pauwels,et al.  Burden and clinical features of chronic obstructive pulmonary disease (COPD) , 2004, The Lancet.

[49]  L. Trupin,et al.  The occupational burden of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[50]  Joan B Soriano,et al.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.

[51]  M. Nishimura,et al.  COPD in Japan: the Nippon COPD Epidemiology study , 2004, Respirology.

[52]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[53]  E. Wagner Chronic disease care , 2004, BMJ : British Medical Journal.

[54]  Ramon Gisbert,et al.  Clinical InvestigationsBronchitisCosts of Chronic Bronchitis and COPDa: A 1-Year Follow-up Study , 2003 .

[55]  G. Little,et al.  The natural history of chronic bronchitis and emphysema , 1979 .

[56]  D. Mannino,et al.  Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. , 2006, Respiratory medicine.

[57]  Alan D. Lopez,et al.  Global burden of disease and risk factors , 2006 .

[58]  N. Anthonisen,et al.  Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases. , 2005, Canadian respiratory journal.

[59]  S. Hashimoto,et al.  Incidence of Chronic Obstructive Pulmonary Disease, and the Relationship between Age and Smoking in a Japanese Population , 2007, Journal of epidemiology.

[60]  K. Morgan,et al.  A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. , 2000, Chest.

[61]  N. Anthonisen Chronic obstructive pulmonary disease. , 1988, Canadian respiratory journal.

[62]  E. Silverman,et al.  Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[63]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[64]  P. Enright,et al.  Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. , 2002, The New England journal of medicine.

[65]  G. Snider Nosology for our day: its application to chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[66]  A. Jemal,et al.  Trends in the leading causes of death in the United States, 1970-2002. , 2005, JAMA.

[67]  R. Rodríguez-Roisín,et al.  Improving the care of COPD patients - suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.

[68]  T. Seemungal,et al.  Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[69]  C. D. Mathers,et al.  Chronic obstructive pulmonary disease: current burden and future projections , 2006, European Respiratory Journal.

[70]  E H Wagner,et al.  Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.

[71]  W. Bailey,et al.  Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. , 2006, American journal of respiratory and critical care medicine.

[72]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[73]  S. Uh,et al.  Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. , 2005, American journal of respiratory and critical care medicine.

[74]  J. Vestbo,et al.  Update on the "Dutch hypothesis" for chronic respiratory disease , 1998, Thorax.

[75]  M. Miravitlles,et al.  Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional , 2004 .

[76]  W. MacNee,et al.  Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[77]  Kiros Berhane,et al.  Effects of glutathione S-transferase M1, maternal smoking during pregnancy, and environmental tobacco smoke on asthma and wheezing in children. , 2002, American journal of respiratory and critical care medicine.

[78]  T. Seemungal,et al.  COPD exacerbations: defi ning their cause and prevention , 2007 .

[79]  S. Johnston,et al.  Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. , 2005, Proceedings of the American Thoracic Society.

[80]  A. Gulsvik,et al.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.

[81]  A. Iqbal,et al.  Interpreting COPD prevalence estimates: what is the true burden of disease? , 2003, Chest.

[82]  D. Mannino,et al.  Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.

[83]  James K Stoller,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[84]  N. Laird,et al.  The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). , 2004, Human molecular genetics.

[85]  Scott T. Weiss,et al.  The transforming growth factor-β1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD) , 2004 .

[86]  P. Yang,et al.  Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD , 2004, European Respiratory Journal.

[87]  K. Kimm,et al.  The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[88]  S. Rennard COPD: overview of definitions, epidemiology, and factors influencing its development. , 1998, Chest.

[89]  Predictors of lung function and its decline in mild to moderate COPD in association with gender : Results from the Euroscop study , 2006 .